Bocidelpar
pharmaceutical compound
Bocidelpar (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names ASP-0367, MA-0211, and MTB-1) is a peroxisome proliferator-activated receptor delta (PPARδ) agonist which is or was under development for the treatment of mitochondrial myopathies, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), Duchenne muscular dystrophy, and metabolic disorders. It is taken orally.
The clinical pharmacodynamics and pharmacokinetics of bocidelpar have been studied.
Bocidelpar was originated by Mitobridge and is under development by Astellas Pharma and Mitobridge. As of February 2026, bocidelpar is in phase 2/3 clinical trials for mitochondrial myopathies and phase 2 trials for ME/CFS, whereas no recent development has been reported for Duchenne muscular dystrophy or metabolic disorders. However, other sources state that bocidelpar has been discontinued. The drug was also under development for the treatment of hypoxia, but development for this indication was discontinued. A phase 2 trial for mitochondrial myopathies was terminated due to lack of effectiveness.
Begin with the source’s own compact description: “Bocidelpar” is pharmaceutical compound. The dossier treats that line as a proposition to test through Bocidelpar, pharmaceutical and compound, not as a finished interpretation.
Why this record matters
The phrase “pharmaceutical compound” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Aug 21, 2026. The linked authority identifier is Q139023034. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2026.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Bocidelpar”, its source revision and the description used here.
- Expand the search: follow Bocidelpar primary sources, Bocidelpar archive and Bocidelpar research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Bocidelpar”?
- What terminology or title could unlock a more precise catalogue search?
- Which cited source is closest to the event, object or claim?
Search terms from this dossier
This entry incorporates text from “Bocidelpar” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.